Scarica l'app Stockscreener
73.77
0.20%
0.15
Dopo l'orario di chiusura:
73.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Shares - GuruFocus
Cytokinetics director Robert Landry sells $74,660 in shares By Investing.com - Investing.com South Africa
Cytokinetics director Robert Landry sells $74,660 in shares - Investing.com
Cytokinetics (NASDAQ: CYTK) director plans 2,000-share Rule 144 sale - Stock Titan
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Cantor Fitzgerald reiterates Overweight on Cytokinetics stock By Investing.com - Investing.com Australia
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com Nigeria
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03 - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes - investing.com
Cytokinetics (CYTK) Insider Sell: EVP Research & Development Fad - GuruFocus
Could Aficamten Give Cytokinetics the First Approved nHCM Treatment? - Yahoo Finance
Cytokinetics, Inc. (CYTK) Stock Analysis: Biotech Growth With 51% Upside Potential - DirectorsTalk Interviews
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - Zacks Investment Research
Cytokinetics to Participate in September Investor Conferences - marketscreener.com
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects? - Eastern Progress
Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $357,400, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (NASDAQ: CYTK) director sale under 10b5-1 plan - Stock Titan
Cytokinetics (NASDAQ: CYTK) director moves to sell 5,000 vested shares - Stock Titan
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $112 - Moomoo
Cytokinetics (CYTK) Presents New Phase 3 Data, Is It Still 34% Undervalued? - Yahoo Finance
Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential - Investing.com
Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential By Investing.com - Investing.com Canada
Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM - Yahoo Finance
CYTK5615147 Bond Profile — Key Metrics - TradingView
Cytokinetics (CYTK) CEO exercises options, sells 7,500 shares - Stock Titan
What's Going On With Cytokinetics Stock Today?Cytokinetics (NASDAQ:CYTK) - Benzinga
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy - BioPharma Dive
Cytokinetics, Inc. (CYTK) Stock Analysis: A Biotech Powerhouse with 52.45% Upside Potential - DirectorsTalk Interviews
Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCMHas The Bull Case Changed? - webull.com
Cytokinetics Announces Additional ACACIA-HCM and MAPLE-HCM Results Showing Aficamten Benefits Across Hypertrophic Cardiomyopathy Spectrum - Quiver Quantitative
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
ESC: Cytokinetics Confirms Strong Case For Myqorzo Label Expansion - insights.citeline.com
If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Why Cytokinetics (CYTK) Stock Is Down Today - Quiver Quantitative
Cytokinetics details trial win for what could be its next approval - STAT
Cytokinetics Announces Positive Phase 3 ACACIA-HCM Results for Aficamten in Non-Obstructive Hypertrophic Cardiomyopathy - Quiver Quantitative
Cytokinetics' aficamten showed gains in patient scores and exercise in Phase 3 trial - Stock Titan
Cytokinetics (CYTK) Institutional Ownership 2026 $CYTK - MarketBeat
News on AstraZeneca, Cytokinetics, Novartis and more — what to look out for at ESC 2026 - Endpoints News
Cytokinetics, Incorporated (CYTK) Stock Analysis: Evaluating a Potential 43% Upside in the Biotech Sector - DirectorsTalk Interviews
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 - Yahoo Finance
Cytokinetics succeeds where Bristol Myers failed in heart muscle disease - Endpoints News
Cytokinetics to Present ACACIA-HCM Hot Line Results and Host Investor Event at ESC Congress 2026 - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) ... - Caledonian Record
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? - Eastern Progress
Cytokinetics (CYTK) EVP Research & Development Fady Malik Sells 3,500 Shares - GuruFocus
Cytokinetics EVP Fady Ibraham Exercises Stock Options and Sells 3,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Cytokinetics EVP research & development sells $265,370 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP research & development sells $265,370 in stock - Investing.com
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $265,370.00 in Stock - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
0.24%
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):